Personalis, Inc. (PSNL)
About Personalis, Inc.
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. The company' products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.
This profile is unclaimed. An authorized representative can claim it free to control the page and activate the embeddable Verified badge.
Financial summary
- Revenue FY2025
- $69.6M
- Net income
- -$81.3M
- Total assets
- $334.2M
- Market cap
- $1.3B
Source: SEC EDGAR · updated Jun 7, 2026
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $1.3B
- Shares outstanding
- 79.3M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jun 20, 2019
Personalis, Inc. (PSNL) Stock Price
- Reported a net loss of $81.3M in FY2025.
- Trading 14% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Personalis, Inc..
Write a review
News about Personalis, Inc.
News & sentiment via Polygon.io
Personalis, Inc.: frequently asked questions
Is Personalis, Inc. an American company?
Personalis, Inc. is a US-based company headquartered in Fremont, California, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Where is Personalis, Inc. headquartered?
Personalis, Inc. is headquartered in Fremont, California, United States.
Is Personalis, Inc. publicly traded?
Yes — Personalis, Inc. is a publicly traded company. Its stock trades under the ticker symbol PSNL on the NASDAQ.
What does Personalis, Inc. do?
Personalis, Inc. is an American Medical Devices company in the Health & Beauty sector.
